Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Divestments (2019)

Avalo Therapeutics filings provide 1 years of Divestments readings, the most recent being $4.0 million for Q4 2019.

On a quarterly basis, Divestments changed N/A to $4.0 million in Q4 2019 year-over-year; TTM through Sep 2021 was $4.0 million, a N/A change, with the full-year FY2020 number at $12.8 million, up 224.3% from a year prior.
Divestments hit $4.0 million in Q4 2019 for Avalo Therapeutics.
In the past five years, Divestments ranged from a high of $4.0 million in Q4 2019 to a low of $4.0 million in Q4 2019.